Group 1 - The Guizhou Provincial Drug Administration has lifted the suspension of production and sales for Guizhou Yibai Pharmaceutical Co., Ltd.'s pediatric cough syrup [2] - The production line for the syrup has completed the necessary rectifications by September 16, 2025, and the results meet the required standards [2] - The announcement is based on the regulations outlined in the Drug Production Supervision and Administration Measures and the Drug Inspection Management Measures (Trial) [2]

Group 1 - Shudao Equipment's subsidiary signed a construction contract worth 24.68 million yuan for a hydrogen fuel cell manufacturing base project [1] - Zhongliang Technology received a land acquisition compensation of 30 million yuan from the government [2] - Palm Holdings won a bid for a high-standard farmland construction project in Lankao County, with a contract value of 433 million yuan, accounting for 14.12% of the company's audited revenue for 2024 [3] Group 2 - Changchun Yidong's subsidiary received a government subsidy of 2.85 million yuan, which is 122.78% of the company's audited net profit for the last fiscal year [4] - Wuzhou Transportation successfully issued 200 million yuan in medium-term notes with an interest rate of 2.10% [5][6] - Tiandi Source's subsidiary plans to apply for a trust loan of up to 500 million yuan from related parties [8] Group 3 - Tiandi Source's subsidiary acquired a residential land use right in Xi'an for 2.015 billion yuan [9] - Opcon Vision received a medical device registration certificate for its ultrasonic nebulizer [11] - Jingjiawei announced the resignation of its vice president due to personal reasons [13] Group 4 - Fulinh Precision's subsidiary received a prepayment of 1.5 billion yuan from CATL for securing lithium iron phosphate material supply [15] - Yunzhu Technology's subsidiary received a government subsidy of 20.12 million yuan [16] - Kehua Bio's ferritin test kit received a medical device registration certificate [17] Group 5 - Jinghua Pharmaceutical's medical sodium alginate wound dressing received a medical device registration certificate [18] - Lingwei Technology established a wholly-owned subsidiary with a registered capital of 1 million yuan [19] - Sanwei Co. won a bid for concrete sleeper procurement projects worth 158 million yuan [20] Group 6 - Shanghai Pharmaceuticals' Nicardipine tablets passed the consistency evaluation for generic drugs [21] - Lushan New Materials increased its idle fund management limit to 750 million yuan [24] - Huayi Technology announced the retirement of a core technical staff member [25] Group 7 - Yingli Environment plans to use up to 300 million yuan of idle raised funds for cash management [30] - Yong'an Forestry plans to develop a national reserve forest project in Putian, Fujian, with an estimated investment of 154 million yuan [32] - Xinyuan Technology's shareholders plan to reduce their holdings by up to 3.18% of the company's shares [60]

Group 1 - The company Yibai Pharmaceutical announced on September 17 that it received a notice from the Guizhou Provincial Drug Administration to suspend the production and sale of its pediatric cough syrup effective from August 2025 [2] - Following rectification, the company received a notice on September 16, 2025, lifting the suspension of production and sales [2]

Group 1 - Yibai Pharmaceutical received a notice from the Guizhou Provincial Drug Administration on September 16, 2025, lifting the suspension of production and sales of its children's cough syrup due to resolved safety concerns [1] - The company had previously suspended the production and sales of the children's cough syrup in August 2025, following a notification from the same authority [1] - Revenue from the children's cough syrup for the years 2021, 2022, 2023, and 2024 was 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total revenue during those years, indicating a relatively small impact on overall performance [1] Group 2 - In the first half of the year, the company reported a revenue of 993 million, a year-on-year decrease of 14.99%, and a net loss attributable to shareholders of 19.90 million [2] - The primary reason for the loss was a decrease in sales of major products, while costs remained higher than revenue; however, improved cost control measures led to a reduction in losses compared to the previous year [2] - The company is actively expanding into chemical drugs, traditional Chinese medicine, and biological drugs, focusing on building a robust R&D system and integrating advantageous resources for innovative drug development [2] Group 3 - The company is exploring existing products with unique or similar exclusivity and conducting research on ancient classic formula compound preparations [3] - Research efforts include safety re-evaluation studies for Ginkgo Biloba injection and quality studies for Aidi injection, with preliminary completion of quality standard enhancement for Ginkgo Biloba injection [3] - As of June 30, 2025, the company completed the registration of 412 new products, including 248 national standard products and 164 provincial standard products [3]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) has temporarily suspended the production and sales of its children's cough syrup due to safety concerns, but has since resolved the issues and resumed operations, with minimal impact expected on overall performance [1] Financial Performance - Revenue from children's cough syrup for the years 2021, 2022, 2023, and 2024 was 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total consolidated revenue [1]

贵州益佰制药股份有限公司 关于收到贵州省药品监督管理局 《暂停生产/销售解除通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 8 月，贵州益佰制药股份有限公司（以下简称"公司"）收到贵州省 药品监督管理局（以下简称"贵州省药监局"）出具的《暂停生产、销售通知书》 （黔药监生产（药化）暂停［2025］4 号），自收到本通知书后公司立即暂停小 儿止咳糖浆生产、销售。详情请参见公司披露在《证券时报》《证券日报》《上海 证券报》《中国证券报》及上海证券交易所网站的《关于收到贵州省药品监督管 理局<暂停生产、销售通知书>的公告》（公告编号：2025-021）。 经整改，公司于 2025 年 9 月 16 日收到贵州省药品监督管理局出具的《暂停 生产/销售解除通知书》（黔药监生产（药化）停解［2025］6 号），现将相关情 况公告如下： 一、《暂停生产/销售解除通知书》的主要内容 证券代码：600594 证券简称：益佰制药 公告编号:2025-029 特此公告。 贵州益佰制药股份有限公司董事会 贵州益佰制药股份 ...

Core Viewpoint - The company has resumed the production and sales of its pediatric cough syrup after receiving a notice of suspension from the Guizhou Provincial Drug Administration, which was lifted following corrective actions taken by the company [1] Financial Performance - Revenue from the pediatric cough syrup for the years 2021 to 2024 was recorded at 3.42 million, 4.32 million, 8.38 million, and 1.51 million respectively [1] - The revenue from this product represents a small proportion of the company's total consolidated revenue during the same periods, indicating that the impact of the resumption on overall performance is expected to be minimal [1]

Core Viewpoint - Yibai Pharmaceutical (600594) announced the suspension of production and sales of its pediatric cough syrup due to a notice from the Guizhou Provincial Drug Administration, but has since resumed operations after rectification, with no significant impact expected on the company's performance [1] Group 1 - On August 2025, the company received a notice from the Guizhou Provincial Drug Administration to suspend production and sales of its pediatric cough syrup [1] - The company immediately halted production and sales upon receiving the notice [1] - After rectification, the company received a notice on September 16, 2025, lifting the suspension, allowing it to resume production and sales [1] Group 2 - The company anticipates that the suspension will not have a significant impact on its overall performance [1]

Core Viewpoint - The company plans to sell a total of 8.686 million shares of Guizhou Yibai Pharmaceutical, 970,600 shares of Aorui De, 7,716 shares of China Ping An, and 4.7122 million shares of Hunan Erkang Pharmaceutical, aiming to optimize its asset structure and improve liquidity and efficiency [1] Group 1 - The estimated profit from the sale of these stocks, after deducting costs and taxes, is expected to exceed 50% of the company's audited net profit for the last year [1] - The sale is intended to enhance the company's asset liquidity and utilization [1] - The company is strategically timing the sale based on stock market conditions [1]

Core Viewpoint - The company plans to sell a significant number of shares in various companies based on market conditions, which is expected to yield substantial profits exceeding 50% of its audited net profit from the last year [1] Group 1: Share Sales - The company intends to sell 8.686 million shares of Guizhou Yibai Pharmaceutical Co., Ltd. [1] - The company plans to sell 970,600 shares of Aorui De Optoelectronics Co., Ltd. [1] - The company will sell 7,716 shares of China Ping An Insurance (Group) Company [1] - The company aims to sell 4.7122 million shares of Hunan Erkang Pharmaceutical Co., Ltd. [1] Group 2: Financial Impact - The estimated profit from the sale of these shares, after deducting holding costs and related taxes, is projected to account for over 50% of the company's audited net profit from the previous year [1]